Incidence of Second Malignancy in Patients with Papillary Thyroid Cancer from Surveillance, Epidemiology, and End Results 13 Dataset
Table 2
Frequency and standardized incidence ratio of SPM by radiation.
None/unknown
Radioisotopes
Beam radiation
Observed
O/E
95% CI
Observed
O/E
95% CI
Observed
O/E
95% CI
All sites
1,511
1.09#
1.03–1.14
1,124
1.16#
1.1–1.23
82
1.15
0.92–1.43
All solid tumors
1,356
1.09#
1.03–1.15
981
1.13#
1.06–1.2
75
1.19
0.93–1.49
Oral cavity and pharynx
21
0.77
0.48–1.18
34
1.70#
1.18–2.38
3
2.33
0.48–6.81
Salivary gland
6
1.78
0.65–3.87
19
7.88#
4.74–12.3
2
12.44#
1.51–44.95
Colon, rectum and anus
115
0.83#
0.69–1
85
0.94
0.75–1.16
15
1.88#
1.05–3.11
Colon excluding rectum
89
0.92
0.74–1.13
62
1.02
0.78–1.31
12
2.08#
1.07–3.63
Rectum
15
0.56#
0.32–0.93
13
0.69
0.37–1.18
2
1.46
0.18–5.27
Bones and joints
5
3.10#
1.01–7.24
5
3.94#
1.28–9.2
0
0
0–50.45
Skin
80
1.24
0.99–1.55
68
1.42#
1.1–1.8
4
1.48
0.4–3.8
Melanoma
72
1.22
0.96–1.54
59
1.34#
1.02–1.72
4
1.65
0.45–4.22
Breast
356
1.12#
1.01–1.24
245
1.08
0.95–4.7
24
1.4
0.9–2.08
Prostate
152
1.22#
1.03–1.43
126
1.40#
1.17–1.68
8
1.95
0.84–3.84
Testis
3
1.97
0.41–5.77
4
2.2
0.6–1.67
0
0
0–67.97
Urinary system
151
1.67#
1.41–1.95
90
1.49#
1.2–5.64
6
1.41
0.52–3.07
Urinary bladder
72
1.42#
1.11–1.79
32
1
0.68–1.83
2
0.87
0.11–3.14
Kidney and renal pelvis
71
1.89#
1.47–2.38
57
2.13#
1.61–2.75
3
1.65
0.34–4.81
Kidney
63
1.80#
1.38–2.3
55
2.18#
1.65–2.82
3
1.79
0.37–524
Renal pelvis
8
3.03#
1.31–5.97
2
1.22
0.15–2.84
0
0
0–24.65
Ureter
6
3.97#
1.46–8.65
1
1.07
0.03–4.42
1
11.92
0.3–66.4
Brain and other nervous system
16
1.05
0.6–1.71
20
1.78#
1.08–5.95
0
0
0–5.04
Brain
15
1.05
0.59–1.73
18
1.70#
1.01–2.74
0
0
0–5.35
All lymphatic and hematopoietic diseases
128
1.12
0.94–1.34
116
1.50#
1.24–20.92
4
0.67
0.18–1.72
Lymphoma
69
1.12
0.87–1.42
1.16
52
0.9–1.8
0
0
0–1.16
Hodgkin lymphoma
4
0.87
0.24–2.22
5
1.28
0.42–1.59
0
0
0–18.28
Non-Hodgkin lymphoma
65
1.14
0.88–1.45
47
1.2
0.88–2.99
0
0
0–1.24
Myeloma
23
1.28
0.81–1.91
14
1.2
0.66–1.6
1
0.99
0.03–5.54
Leukemia
36
1.05
0.74–1.46
50
2.20#
1.63–2.01
3
1.7
0.35–4.96
Lymphocytic leukemia
18
1.08
0.64–1.7
20
1.82#
1.11–2.9
1
1.19
0.03–6.61
Acute lymphocytic leukemia
8
5.03#
2.17–9.91
4
3.12
0.85–2.81
1
13.78
0.35–76.76
Chronic lymphocytic leukemia
10
0.71
0.34–1.31
16
1.78#
1.02–8
0
0
0–5.09
Nonlymphocytic leukemia
18
1.03
0.61–1.62
30
2.55#
1.72–2.9
2
2.16
0.26–7.82
Acute nonlymphocytic leukemia (ANLL)
14
1.19
0.65–2
19
2.40#
1.45–3.64
1
1.61
0.04–8.99
Myeloid and monocytic leukemia
17
1.07
0.62–1.71
28
2.59#
1.72–3.75
2
2.43
0.29–8.77
Acute myeloid leukemia
13
1.25
0.67–2.14
18
2.54#
1.51–3.74
1
1.83
0.05–10.22
Chronic myeloid leukemia
3
0.67
0.14–1.96
9
2.92#
1.34–12.93
1
4.41
0.11–24.58
Cancers without statistically significant elevated risk are excluded, except for ones related to other statistically significant cancers; #: value < 0.05; 95% CI: 95% confidence interval.
